HNF1A and MODY: With the establishment of sulfonylureas as the treatment of choice for HNF1A-MODY [16], molecular diagnosis of monogenic diabetes has been solidified as a necessary clinical tool with important prognostic implications, being part of clinical routine for patients with a clinical suspicion of MODY.